Because of the way Chinese pharmaceutical companies do business with the US, they’re largely exempt from President Donald Trump’s recently announced 100% levy on patented drugs. It’s too soon to breathe easy. A slew of regulatory risks from Washington persists for an industry that simultaneously enjoys a deeply interdependent relationship with its American partners while also being seen as an existential threat.
In January, DeepSeek surprised the world by introducing a low cost, effective open-source language model. Two months later, electric vehicle maker BYD Co. unveiled a five-minute charging system, only to be seemingly outdone by rival battery supplier Contemporary Amperex Technology Co. in April.